- ISIN
- US75382E1091
- CUSIP
- 75382E109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 31, 2019
Highlights
- Market Cap
- $1.56B
- Enterprise Value
- $1.53B
- EPS (TTM)
- -$3.92
- Gross Profit (TTM)
- -$200.00K
- EBITDA (TTM)
- -$108.01M
- Year Range
- $6.88 - $58.02
- ROA (TTM)
- -63.74%
- ROE (TTM)
- -69.51%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RAPT Performance Chart
Loading charts...
Returns By Period
RAPT Therapeutics, Inc.
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
RAPT Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 70.30% | 0.52% | 0.07% | 71.30% | |||||||||
| 2025 | -27.85% | -0.00% | 7.02% | -24.03% | -4.48% | 12.96% | 35.00% | 5.37% | 126.63% | 17.14% | 11.88% | 0.21% | 167.96% |
| 2024 | -0.40% | -65.37% | 4.78% | -14.25% | -47.92% | -23.94% | 2.95% | -34.55% | -2.19% | 5.47% | -40.57% | 25.40% | -93.64% |
| 2023 | 46.72% | 1.38% | -37.69% | -0.82% | 10.05% | -6.64% | 27.81% | -20.08% | -12.98% | -20.88% | 10.42% | 71.14% | 25.51% |
| 2022 | -41.14% | -7.49% | 9.95% | -31.20% | -2.71% | 23.98% | 0.93% | 45.01% | -9.92% | -9.31% | -18.97% | 11.99% | -46.09% |
| 2021 | 0.86% | -8.89% | 22.31% | -1.17% | -12.03% | 64.72% | -3.52% | 6.62% | -5.05% | 1.71% | 3.39% | 12.50% | 85.97% |
Benchmark Metrics
RAPT Therapeutics, Inc. has an annualized alpha of 57.86%, beta of 1.28, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 01, 2019.
- This stock participated in 108.43% of S&P 500 Index downside but only 28.72% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 57.86%
- Beta
- 1.28
- R²
- 0.04
- Upside Capture
- 28.72%
- Downside Capture
- 108.43%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for RAPT Therapeutics, Inc. (RAPT) and compare them to S&P 500 Index.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the RAPT Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the RAPT Therapeutics, Inc. was 98.47%, occurring on May 13, 2025. The portfolio has not yet recovered.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -98.47%May 2025 | 5y 3mo | — | 6y 4moJan 2020 - now |
2019 bear market2019 | -36.69%Nov 2019 | 7d | 7d | 14dNov 2019 - Nov 2019 |
2019 bear market2019 | -26.43%Dec 2019 | 16d | 11d | 27dNov 2019 - Dec 2019 |
2019 correction2019 | -13.65%Dec 2019 | 4d | 8d | 12dDec 2019 - Jan 2020 |
2020 correction2020 | -11.35%Jan 2020 | 3d | 3d | 6dJan 2020 - Jan 2020 |
Drawdown Indicators
| RAPT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | -0.74% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.72% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 1.97% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of RAPT Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how RAPT Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RAPT in comparison with other companies in the Biotechnology industry. Currently, RAPT has a P/B value of 10.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RAPT
Add RAPT Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RAPT